RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients
John D. Isaacs, Sarah Brockbank, Ayako Wakatsuki Pedersen, Catharien M. U. Hilkens, Amy E. Anderson, Philip Stocks, Dennis Lendrem, Jessica Tarn, Graham R. Smith, Ben Allen, John Casement, Julie Diboll, Rachel A. Harry, Faye A. H. Cooles, Andrew P. Cope, Gemma Simpson, Ruth Toward, Hayley Noble, Angela Parke, Wing Cheung Vincent Wu, Fiona Clarke, David L. Scott, Ian C. Scott, James Galloway, Heidi Lempp, Fowzia Ibrahim, Samana Schwank, Gemma Molyneux, Tomi Lazarov, Frédéric Geissmann, Carl S. Goodyear, Iain B. McInnes, Iona Donnelly, Ashley Gilmour, Aysın Tulunay Virlan, Duncan Porter, Frédérique Ponchel, Paul Emery, Jehan J. El‐Jawhari, Rekha Parmar, Michael McDermott, Benjamin A. Fisher, Steve Young, Philip Jones, Karim Raza, Andrew Filer, Costantino Pitzalis, Michael R. Barnes, David Watson, Rafael Henkin, Georgina Thorborn, Liliane Fossati‐Jimack, Stephen Kelly, Frances Humby, Michele Bombardieri, Sharmila Rana, Zhilong Jia, Katriona Goldmann, Myles Lewis, Sandra Ng, Adriano Barbosa-Silva, Evan Tzanis, Amaya Gallagher-Syed, Christopher R. John, Michael R. Ehrenstein, Gioia Altobelli, Sandra Martins, Dao X. Nguyen, Humayara Ali, Coziana Ciurtin, Maya H Buch, Deborah Symmons, Jane Worthington, Ian N Bruce, Jamie C. Sergeant, Suzanne Verstappen, F. Stirling, Adwoa Hughes-Morley, Brian D. M. Tom, Vernon T. Farewell, Yujie Zhong, Peter C. Taylor, Christopher D. Buckley, Sarah Keidel, Carolyn A. Cuff, Marc C. Levesque, Andrew J. Long, Zheng Liu, Samantha Lipsky, Bohdan P. Harvey, Michael Macoritto, Feng Hong, Şükrü Kaymakçalan, Wayne Tsuji, Tony Sabin, Neil Ward, Susan Talbot, Desmond Padhji, Matthew A. Sleeman, Donna K. Finch
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disorder with poorly defined aetiology characterised by synovial inflammation with variable disease severity and drug responsiveness. To investigate the peripheral blood immune cell landscape of early, drug naive RA, we performed comprehensive clinical and molecular profiling of 267 RA patients and 52 healthy vaccine recipients for up to 18 months to establish a high quality sample biobank including plasma, serum, peripheral blood cells, urine, genomic DNA, RNA from whole blood, lymphocyte and monocyte subsets. We have performed extensive multi-omic immune phenotyping, including genomic, metabolomic, proteomic, transcriptomic and autoantibody profiling. We anticipate that these detailed clinical and molecular data will serve as a fundamental resource offering insights into immune-mediated disease pathogenesis, progression and therapeutic response, ultimately contributing to the development and application of targeted therapies for RA.